---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-049870"
form_type: "8-K"
ticker: "TERN"
cik: "0001831363"
company_name: "Terns Pharmaceuticals, Inc."
filed_at: "2024-04-29T23:59:59+00:00"
generated_at: "2026-06-03T05:43:29.915314+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Terns reports TERN-701 Phase 1 PK data: no food effect, once-daily dosing supported

## Summary
- TERN-701 showed no clinically significant food effect at 80 mg; supports dosing with or without food.
- PK linear across 20-160 mg; median half-life 8-12 hours; exposures at 80 and 160 mg met predicted efficacious levels.
- Phase 1 CARDINAL trial in 2L+ CML ongoing; interim dose escalation data expected H2 2024.
- No clinically meaningful changes in lab data, vital signs, or ECG across all dose levels.
- Data consistent with Chinese Phase 1 study; plans to present at upcoming scientific conference.

## SEC filing metadata
- accession: 0000950170-24-049870
- form_type: 8-K
- ticker: TERN
- cik: 0001831363
- company_name: Terns Pharmaceuticals, Inc.
- filed_at: 2024-04-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831363/000095017024049870/0000950170-24-049870-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831363/000095017024049870/tern-20240429.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-049870
- JSON: https://secwatch.observer/filing/0000950170-24-049870.json
- Plain text: https://secwatch.observer/filing/0000950170-24-049870.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.